Home >> Marketplace Archives >> Natera, Institut Jules Bordet collaborate

Natera, Institut Jules Bordet collaborate

Print Friendly, PDF & Email

August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.

Natera will analyze approximately 300 plasma specimens prospectively collected and banked from 80 patients diagnosed with nonmetastatic breast cancer who received neoadjuvant chemotherapy followed by surgery and who were then monitored for recurrence with serial imaging. The study will correlate results of the Signatera assay with clinical outcomes, including pathological response and event-free survival. The study is led by Michail Ignatiadis, MD, PhD, attending physician in the medical oncology department of Institut Jules Bordet and assistant professor, Université Libre de

Natera, 844-778-4700


Check Also

NIPT for screening twin pregnancies, 11/17

November 2017—Natera announced that its Panorama noninvasive prenatal test is validated to screen twin pregnancies for zygosity and chromosomal abnormalities. Panorama can tell the difference between the mother’s and the baby’s DNA, enabling it to distinguish between each twin’s DNA.